Omnicell (NASDAQ:OMCL) Releases Q4 2024 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its fourth quarter 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.550-0.620 for the period, compared to the consensus estimate of 0.470. The company issued revenue guidance of $295.0 million-$305.0 million, compared to the consensus revenue estimate of $287.9 million. Omnicell also updated its FY 2024 guidance to 1.650-1.720 EPS.

Omnicell Stock Performance

Shares of Omnicell stock traded up $0.03 on Friday, reaching $48.67. 683,792 shares of the company were exchanged, compared to its average volume of 528,146. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.74. The company has a quick ratio of 2.22, a current ratio of 1.05 and a debt-to-equity ratio of 0.47. The company’s 50-day moving average is $43.26 and its two-hundred day moving average is $35.17.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.14 by $0.37. The firm had revenue of $276.80 million during the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a negative net margin of 1.66% and a positive return on equity of 2.55%. Omnicell’s quarterly revenue was down 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.29 EPS. On average, equities research analysts forecast that Omnicell will post 0.64 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Barclays increased their price objective on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday. Bank of America reissued a “neutral” rating and issued a $57.00 price target (up previously from $44.00) on shares of Omnicell in a research note on Thursday. Craig Hallum upped their price objective on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday. Benchmark reissued a “buy” rating and issued a $48.00 target price on shares of Omnicell in a research report on Wednesday, October 9th. Finally, JPMorgan Chase & Co. upped their price target on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $49.14.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.